Roivant Sciences Ltd. (ROIV): Total Assets
$5.71B
As of 2026-03-31
$5.31B
As of 2026-06-30
+33.7%
3-year compound annual growth
+17.1%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $5.71B | +5.0% | 2026-05-20, Balance as of period end |
| 2025-03-31 | $5.44B | -24.7% | 2026-05-20, Balance as of period end |
| 2024-03-31 | $7.22B | +202.2% | 2025-05-29, Balance as of period end |
| 2023-03-31 | $2.39B | -7.6% | 2024-05-30, Balance as of period end |
| 2022-03-31 | $2.59B | -0.2% | 2023-06-28, Balance as of period end |
| 2021-03-31 | $2.59B | n/a | 2022-06-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $5.71B | +5.0% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $49.95M | +12.6% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $160.46M | -27.2% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $56.75M | -43.0% |
| Adagene Inc. (ADAG) | 2025-12-31 | $78.26M | -12.3% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $294.89M | -17.7% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $633.16M | -20.7% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.82M | -6.8% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $150.93M | +63.8% |
Compare ROIV, COYA, ACRS, BOLT side by side · Screen every company in Pharmaceutical Preparations ↗